Stockreport

Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study [Financial Post (Toronto, Ontario, Canada)]

Medicenna Therapeutics Corp. - Common Shares  (MDNA) 
PDF — Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021 — Preliminary efficacy readouts from study expected over the course of 2022 TORO [Read more]